Sanophi is a global life sciences company committed to improving access to healthcare and supporting the people we serve throughout the continuum of care. From prevention to treatment, Sanophi transforms scientific innovation into healthcare solutions, in human vaccines, rare diseases, multiple sclerosis, oncology, immunology, infectious diseases, diabetes and cardiovascular solutions and consumer healthcare. More than 110,000 people at Sanophi are dedicated to make a difference on patients’ daily life, wherever they live and enable them to enjoy a healthier life.
We concentrate our research efforts where the most pressing medical needs and public health issues are, bringing solutions to patients and contributing to a healthier society worldwide:
At Sanophi, we have a clear and resolute line for action: to contribute to the continuous advancement of health. As a company, and as individuals, Sanophi and its talented employees have always striven to advance the cause of health by developing treatments that prevent and treat diseases, while enhancing access to healthcare for the people around the world.
The expertise we have developed along the way has had a profound effect, particularly in the developing world. We have developed the first vaccine for the dengue virus, which infects 390 million people each year, and whose range is expanding due to climate change. Since the beginning of the year, first vaccinations campaigns have started in the Philippines. Thanks to systematic vaccination campaigns, we are close to eradicating polio; while over the last decade, sleeping sickness treatments have saved more than 180,000 lives.
Every employee has the opportunity to broaden skills and develop expertise that will make a positive impact on the company’s success, and theirs.
Members of the workforce plays a critical role in exploring new opportunities and roles within the company with the support and guidance of their manager. International mobility opportunities arise when there is a need to transfer skills or knowledge, or as part of a defined talent development plan.
Preventing and Treating
January 4, 2017 - Sanophi Announces Soliqua™ 100/33 Now Available in the U.S.
January 2, 2017 - Sanophi and Boehringer Ingelheim confirm Closing of business swap on January 1st 2017
December 8, 2016 - Sanophi and Regeneron Announce Marketing Authorization Application for Dupixent® (dupilumab) Accepted for Review by the EMA
November 21, 2016 - Sanophi Receives FDA Approval of Soliqua™ 100/33, for the Treatment of Adults with Type 2 Diabetes